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1. Introduction 
In 1988 Sudoh and colleagues described a novel natriuretic peptide in porcine brain -- brain 
natriuretic peptide(Sudoh et al. 1988). In fact, the peptide is most abundant in the heart and 
thus it is now commonly termed B-type natriuretic peptide (BNP). Myocyte pressure and/or 
stretch results in the release of BNP, and BNP levels are easily quantified by several 
commercially available assays. Data from numerous studies have now firmly established a 
role for BNP as a biomarker for diagnosis, prognostication, and management of adults with 
cardiac disease, including those undergoing cardiac surgery(Silver et al. 2004; Mitchell and 
Webb 2011; Rodseth, Padayachee, and Biccard 2008; Fellahi et al. 2011). Unfortunately, far 
fewer data are available on the role of BNP in the management of neonates, infants, and 
children who require cardiac surgery. This chapter will provide a brief review of these data 
in order to understand the potential utility of BNP determinations in this population. 
2. Natriuretic hormone system 
Beginning with the observation by de Bold and colleagues that rats infused with atrial tissue 
extracts developed natriuresis and diuresis, much has been learned over the past three decades 
about the role of the natriuretic hormone system in the homeostatic control of fluid balance 
and vascular tone(de Bold et al. 1981). The natriuretic hormone system comprises several 
related peptides that activate specific receptors, particularly in the kidneys, myocardium, and 
vasculature, which use cyclic guanosine 3’,5’-monophosphate (cGMP) as a second 
messenger(Levin, Gardner, and Samson 1998). These peptides include atrial natriuretic 
peptide (ANP), BNP, C-type natriuretic peptide (CNP), dendroaspis natriuretic peptide 
(DNP), kaliuretic peptide, and urodilantin. The primary stimulus for their release is an 
increase in intravascular or cardiac volume, that causes increased atrial stretch, ventricular 
wall stress, vascular shear stress, intravascular volume, and/or intravascular sodium 
concentration(Levin, Gardner, and Samson 1998). The precise roles of individual natriuretic 
peptides depend upon their distribution and abundance within the cardiovascular system, as 
well as the specific stimulus for their release(Levin, Gardner, and Samson 1998).  
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3. B-Type natriuretic peptide (BNP)  
BNP is predominantly produced in the cardiac ventricles. However under pathologic 
conditions, such as fluid overload, the cardiac atrium can also become a significant source of 
BNP(Sudoh et al. 1988; McGrath, de Bold, and de Bold 2005). Biosynthesis of BNP begins 
with a 134 amino acid precursor, preproBNP. Stimuli, such as myocyte stretch, trigger the 
cleavage of preproBNP forming proBNP, which is subsequently cleaved by a serine protease 
to the active C-terminal 32 amino acid hormone, BNP, and the inactive N-terminal proBNP 
(NT-proBNP). BNP binds to 3 known cell membrane receptors, termed natriuretic peptide 
receptors (NPR-A, NPR-B, and NPR-C). NPR-A and NPR-B are transmembrane receptors 
that activate particulate guanylate cyclase, which catalyzes the conversion of guanosine 
triphosphate to cGMP. The third receptor, NPR-C, is involved in clearance via endocytosis. 
Circulating BNP is also inactivated by cleavage by neutral endopeptidases found in vascular 
cells and renal tubules (Figure 1) (Yandle 1994; Silver et al. 2004). Animal studies suggest 
that approximately half of natriuretic peptide clearance is via the NPR-C receptor and half 
via endopeptidase degradation, but the relative contributions in the human are unclear. 
 
  
Fig. 1. A schematic of B-type natriuretic peptide (BNP) signaling. BNP binds to 3 natriuretic 
peptide receptors (NPR), types A, B, and C, on various target cells located in the 
vasculature, kidney, heart, adrenal glands, and brain. NPR-A and NPR-B are high-affinity 
receptors with an extracellular binding domain, a single membrane-spanning region, and an 
intracellular guanylylcyclase domain. Guanylylcyclase catalyzes the conversion of 
guanosine-5'-triphosphate (GTP) to guanosine-3',5'-cyclic monophosphate (cGMP). BNP is 
degraded by two mechanisms. Neutral endopeptidases degrade circulating BNP, and 
binding to NPR-C results in receptor internalization and degradation by endocytosis. NPR-
C is then recycled to the cell membrance (not shown).  
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The mechanisms that mediate BNP release and metabolism in health and disease are 
incompletely understood. In addition, the effect of development on these mechanisms is 
unknown, but clearly may have great relevance in a pediatric population. Active BNP is 
stored in the atria in specific storage organelles(McGrath, de Bold, and de Bold 2005). Basal 
BNP levels result from continuous secretion from the atria. With acute myocardial 
distention, BNP release increases from this storage pool, in a manner independent of BNP 
synthesis. However, under acute, sub-acute and chronic conditions of increased cardiac 
volume or pressure loading, increases in circulating BNP are maintained due to ventricular 
re-expression of the fetal gene program (Zhang, Carreras, and de Bold 2003; Hama et al. 
1995). In addition to volume and pressure loading, acute myocardial ischemia, α agonist 
stimulation, endothelin-1, and inflammatory mediators, such as tumor necrosis factor-α and 
interleukin-1β, result in rapid ventricular expression of BNP(Hama et al. 1995). The primary 
actions of BNP are vascular smooth muscle relaxation and anti-mitogenesis, mediated by 
cGMP, diuresis, caused by a shift of intravascular volume into the interstitium, and 
natriuresis, caused by antagonism of renin and aldosterone release(McGrath, de Bold, and 
de Bold 2005; Sudoh et al. 1988; Yandle 1994).  
Of all the natriuretic peptides, BNP has emerged as the most useful biomarker for cardiac 
disease. Its major advantage over the other natriuretic peptides is the fact that it is produced 
predominantly in the ventricles, as opposed to the atrium (ANP) or the vascular 
endothelium (CNP)(Silver et al. 2004; Costello, Goodman, and Green 2006). Both active BNP 
and the inactive byproduct of its production, NT-proBNP, are used as biomarkers. BNP 
levels may be better suited to follow dynamic alterations in myocardial performance given 
the shorter circulating half-life of BNP compared to NT-proBNP (20 minutes vs. 60-120 
minutes)(Costello, Goodman, and Green 2006). In addition, the kidneys excrete NT-proBNP, 
and thus renal function, independent of myocardial function, has a greater influence on NT-
proBNP levels than BNP levels.  
Limited data suggest that BNP levels are high at birth but fall during the first week of life, 
reaching levels below adult values by 2 weeks of age. Interestingly, although levels in boys 
tend to decrease with age, girls have an elevation during the second decade of life that is 
associated with puberty (Koch and Singer 2003; Yoshibayashi et al. 1995; Ationu and Carter 
1993).  
4. BNP in pediatric heart disease 
In comparison to the adult experience, there are far fewer data regarding BNP in pediatric 
cardiac disease(Das 2010). Knirsch and colleagues measured BNP levels before and during 
treatment in 522 pediatric patients (age of 6.4±5.2 years, range of 14 days to 18 years) with 
congenital heart disease, cardiomyopathies, or pulmonary arterial hypertension(Knirsch et 
al. 2011). They found that BNP levels were elevated in each type of heart disease, and that 
levels fell in all groups with therapy.  
As opposed to adults with congestive heart failure, BNP levels in infants and children with 
congenital heart disease are quite varied, and are dependent in part upon the age of the 
patient and the specific physiology associated with the cardiac defect. For example, Law and 
colleagues performed a study that included 42 neonates and 58 older children between the 
age of 7 days and 19 years presenting in an acute care setting with symptoms potentially 
attributable to heart disease. BNP levels were higher in both age groups in those patients 
with heart disease compared to those without heart disease, but the cut-off values differed. 
A BNP level of 170 pg/ml was 94% sensitive and 73% specific for heart disease in neonates, 
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whereas a lower level of 41 pg/ml was 87% sensitive and 70% specific for heart disease in 
the older patients(Law et al. 2009).  Koch and colleagues found in a study of 288 pediatric 
patients (mean age of 6 years) with congenital cardiac defects that normal BNP levels did 
not exclude cardiac pathology such as the presence of structural defects or ventricular 
hypertrophy, but rather were associated with the extent of ventricular impairment(Koch, 
Zink, and Singer 2006). Conversely, Cantinotti and colleagues studied 152 neonates with 
congenital heart disease and 154 healthy neonatal controls, and found the BNP levels were 
higher in neonates with congenital heart disease than controls with a diagnostic accuracy 
defined by the area under the curve (on receiver operating characteristic analysis) of 0.935 
for neonates with congenital heart disease between 4 and 30 days of age(Cantinotti et al. 
2010). Thus, it appears that age modifies the diagnostic utility of BNP for cardiac disease in 
pediatric patients. In fact, in a separate study Koch and colleagues demonstrated age-
dependent differences in the metabolic clearance of BNP and NT-proBNP(Koch, Rauh, et al. 
2006).  
A number of studies indicate that cardiopulmonary hemodynamics also modify the 
diagnostic utility of BNP in pediatric patients with congenital heart disease. For example, in 
a study of infants and children with ventricular septal defects, Suda and colleagues found 
that BNP levels correlated with the pulmonary-to-systemic blood flow (Qp:Qs) ratio and the 
mean pulmonary arterial pressure(Suda, Matsumura, and Matsumoto 2003). Koch and 
colleagues demonstrated similar correlations, in their study of 288 patients with various 
cardiac defects(Koch, Zink, and Singer 2006). They found that in patients with left-to-right 
shunts, BNP levels were increased and correlated with shunt volume, systolic right 
ventricular pressure, mean pulmonary artery pressure, and pulmonary vascular 
resistance(Koch, Zink, and Singer 2006). Likewise, Kunii and colleagues compared BNP 
levels between normal children (n=253), and children with ventricular septal defects (n=91), 
patent ductus arteriosus (n=29), and atrial septal defects (n=34). Like the studies of Suda and 
Koch, they found that BNP levels correlated with the Qp:Qs ratio, and also the left 
ventricular end-diastolic volume, and the right ventricular to left ventricular pressure 
ratio(Kunii et al. 2003). Mainwaring and colleagues also found a positive correlation 
between preoperative BNP levels and the Qp:Qs ratio in a study of 18 patients (2 months – 
15.6 years of age) with ventricular septal defects(Mainwaring et al. 2007). Ozhan and 
colleagues found the same relationship between BNP and the Qp:Qs ratio in their study of 
35 children (mean age 70±129 weeks) with ventricular or atrial septal defects. Receiver 
operating characteristic analysis found that a plasma BNP cutoff of ≥20 pg/ml was 69% 
sensitive and 79% specific for a Qp:Qs of greater than 1.5(Ozhan et al. 2007).  
A number of studies of premature neonates found that BNP levels correlated with the 
degree of shunting across a patent ductus arteriosus and predicted hemodynamic 
significance as determined by echocardiography-based criteria(Choi et al. 2005; Flynn et al. 
2005; Puddy et al. 2002; Sanjeev et al. 2005; Holmstrom and Omland 2002; da Graca et al. 
2006). However, the precise cut-off value for BNP that was predictive varied widely. For 
example, Choi and colleagues reported that a BNP level of > 1110 pg/ml was 100% sensitive 
and 95% specific for the presence of a hemodynamically significant patent ductus arteriosus, 
while Sanjeev and colleagues reported a 92% sensitivity with a cut-off level of 70 
pg/ml(Choi et al. 2005; Sanjeev et al. 2005).  
Holmgren and colleagues studied 38 patients with single ventricular physiology. They 
found that BNP levels were higher in patients after first stage palliation (31.6 pg/ml) 
compared to patients after second and third stage palliation (6.7 and 9 pg/ml, respectively). 
In fact, BNP levels in patients after second and third stage palliation did not differ from 
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normal control patients, but interestingly, BNP levels were higher in those patients with 
single ventricles of right ventricular morphology compared to left ventricular 
morphology(Holmgren et al. 2008). In contrast, Koch and colleagues studied 48 patients 
with d-transposition of the great arteries, after arterial switch procedure, or congenitally 
corrected transposition of the great arteries. They found no difference in BNP levels between 
patients with systemic ventricles of right ventricular morphology compared to left 
ventricular morphology(Koch, Zink, and Singer 2008). They did, however, find correlations 
between BNP and the severity of tricuspid regurgitation and decreasing exercise capacity. 
Likewise, Inuzuka and colleagues measured BNP levels in 51 patients (mean age 1.1 years) 
with single ventricular defects undergoing cardiac catheterization before second stage 
palliation. Mean BNP levels were 90.4 pg/ml. BNP levels above 100 pg/ml were associated 
with increased Qp:Qs, end-diastolic volume, AV valve regurgitation, and lower ventricular 
mass to end-diastolic volume ratio, all consistent with an inadequate adaptation to volume 
overload(Inuzuka et al. 2011). In addition, multivariate regression analysis demonstrated 
that the BNP concentration was independently predictive of death or the need for cardiac 
transplantation (with a hazard ratioof 3.05, CI: 1.06-8.83)(Inuzuka et al. 2011).  
Thus, it is clear that BNP determinations can provide physiologically relevant information 
about individual patients, but that finding cut-off values that can be generalized for clinical 
use across the spectrum of congenital heart disease may not be possible. Indeed, in adult 
patients the primary utility of BNP determinations is in establishing the diagnosis of 
congestive heart failure in acute care settings(Maisel et al. 2002). In a pediatric population, 
the questions are more diverse. They might include, when to repair a left-to-right shunt, 
when to proceed with staged palliation of single ventricle defects, or when to refer for 
cardiac transplantation. However, even studies focused on pediatric heart failure have 
revealed a wide range of BNP values, again likely related at least in part to age and 
cardiopulmonary hemodynamics. For example, in a study of infants and children with 
biventricular hearts and chronic left ventricular dysfunction, Price and colleagues found that 
a BNP level of ≥300 pg/ml was predictive of death, hospitalization, or listing for cardiac 
transplant(Price et al. 2006). Shah and colleagues also found that increasing BNP was 
associated with heart failure in their study of 29 patients with single ventricular physiology, 
but with a ten-fold lower cut-off of 30 pg/ml (Shah, et al., 2009).  
5. BNP as a biomarker following cardiac surgery 
5.1 Early post-operative period 
As a cardiac hormone with a relatively short circulating half life that is dynamically released 
in response to deranged myocardial performance, BNP appears perfectly suited for the 
perioperative management of pediatric patients undergoing cardiac surgery for repair or 
palliation of congenital cardiac defects.  
A number of investigators have studied perioperative BNP levels in neonates, infants, and 
children undergoing cardiac surgery. Ationu and colleagues measured perioperative BNP 
levels in 9 children undergoing repair of congenital heart defects(Ationu et al. 1993). In that 
study, BNP levels decreased at 12 hours following surgery(Ationu et al. 1993). Most studies, 
however, have found increases in BNP and NT-proBNP levels after surgery. Costello and 
colleagues measured natriuretic peptide levels, including BNP, in 5 infants undergoing 
surgical repair of left-to-right shunts(Costello et al. 2004). As opposed to ANP and DNP, 
BNP concentrations increased after cardiopulmonary bypass. Sun and colleagues measured 
BNP levels before and after surgery in 27 infants and children undergoing biventricular 
www.intechopen.com
 
Front Lines of Thoracic Surgery 
 
204 
repair and 27 patients undergoing palliation of univentricular congenital heart defects(Sun 
et al. 2005). Plasma BNP levels increased after bypass in patients with biventricular defects, 
but not in patients with univentricular defects(Sun et al. 2005). Costello and colleagues 
examined BNP levels before and following cardiac surgery in 25 infants and children with 
congenital heart disease undergoing complete or palliative repair with the use of 
cardiopulmonary bypass(Costello et al. 2004). BNP levels increased postoperatively, and 
remained elevated over the first postoperative day. The increase in BNP from baseline to 12 
hours was associated with the cardiopulmonary bypass time.Koch and colleagues measured 
BNP levels in 65 pediatric patients (age 4 days – 17 years, mean age of 3.6), undergoing 
surgical repair of congenital cardiac defects preoperatively, and for one week after 
surgery(Koch, Kitzsteiner, et al. 2006). BNP levels increased after surgery (from a median of 
31 pg/ml to 453 pg/ml) and remained elevated over the first week, with a bimodal pattern 
(initial peak at 1.3 days and a second peak at 5.1 days after surgery). Postoperative BNP 
levels correlated with cardiopulmonary bypass time and serum lactate concentrations on the 
first postoperative day.  
Shih and colleagues conducted the first study demonstrating that BNP predicted outcome 
after cardiac surgery in children(Shih et al. 2006). BNP levels were determined before and 
after surgery in 51 patients. They found that BNP levels increased after surgery, peaking at 
12 hours, and that BNP levels 12 hours following surgery were predictive of a requirement 
for mechanical ventilation beyond 48 hours and the presence of low cardiac output 
syndrome within the first 48 hours, postoperatively. Further, the study found that 12-hour 
BNP levels of 540 pg/ml had a sensitivity of 88.9% and a specificity of 82.5% for predicting 
the need for mechanical ventilation beyond 48 hours, and that a 12-hour BNP of 815 pg/ml 
had a sensitivity of 87.5% and a specificity of 90.2% for predicting the development of low 
cardiac output syndrome.  
Similarly, Perez-Piaya and colleagues measured NT-proBNP levels in 68 patients (0-15 years 
of age) undergoing cardiac surgery(Perez-Piaya et al. 2011). They found that NT-proBNP 
levels increased postoperatively, peaking at 24 hours. Moreover, peak NT-proBNP levels 
correlated with risk adjustment congenital heart surgery-1 scores, length of 
cardiopulmonary bypass, inotropic score, duration of mechanical ventilation, and intensive 
care unit length of stay. In addition, preoperative NT-proBNP levels were independent 
predictors of intensive care unit length of stay. Gessler and colleagues also measured NT-
proBNP levels before and after cardiac surgery in 40 children(Gessler et al. 2006). In their 
study, higher preoperative levels were noted in patients with a complicated postoperative 
course.  
It is well known that neonates undergoing cardiac surgery and patients with single 
ventricular physiology represent high-risk groups. Hsu and colleagues examined BNP levels 
before and after surgery in 31 consecutive neonates undergoing repair or palliation of their 
cardiac defects(Hsu et al. 2007). BNP levels at all time points were markedly elevated, 
compared to published normal values. But interestingly, as opposed to the majority of 
studies of older patients, they found that 24-hour postoperative BNP levels were lower than 
preoperative BNP levels in most patients (75%). However, in those patients whose BNP 
levels increased after surgery outcomes were worse. In fact, an increase in post-operative 
BNP was associated with an increased incidence of low cardiac output syndrome (100% vs. 
36 %), and fewer ventilator-free days (17 ± 13 days vs. 25 ± 3 days), and predicted the 6-
month composite endpoint of death, an unplanned operation, or cardiac transplant (57% vs. 
0%). Furthermore, an increase in BNP after surgery had a sensitivity of 100% and a 
specificity of 87% for predicting a poor postoperative outcome. Notably, neither arterial-
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venous oxygen saturation differences (AVdO2) nor lactate levels (or their corresponding 
changes) were associated with postoperative outcomes in this study(Hsu et al. 2007).  
In another neonatal study, Cannesson and colleagues measured perioperative BNP levels in 
30 neonates undergoing the arterial switch operation (ASO) for d-transposition of the great 
arteries(Cannesson et al. 2007). Contrary to the findings of Hsu, BNP levels increased over 
the first 48 hours postoperatively. However, like the study by Hsu these investigators found 
that postoperative BNP levels predicted adverse clinical outcomes, including prolonged 
mechanical ventilation, prolonged stay in the intensive care unit, low cardiac output 
syndrome, and the need for inotropic support. These investigators found that a BNP level of 
>160 pg/ml, 6 hours postoperatively, predicted a complicated postoperative course with a 
sensitivity of 93% and a specificity of 67%. Similarly, Niedner and colleagues studied 102 
neonates and non-neonatal controls undergoing surgical repair for various congenital 
cardiac defects(Niedner et al. 2010). They found that BNP levels increased after surgery, 
peaking at 12 hours. Levels at 24 hours were significantly higher in neonates than in non-
neonates (median of 1506 vs 286 pg/ml). In addition, postoperative BNP levels correlated 
with the inotropic requirement, duration of mechanical ventilation, and intensive care unit 
and hospital length of stay. When comparing the various cardiac defects, these investigators 
found great variability between lesions and noted the significant impact of age, with 
postoperative elevations occurring earlier and to a much greater magnitude in neonates 
compared to older children. One might speculate that the differences between the neonatal 
studies of Hsu, Cannesson, and Niedner relate in part to differences between single and bi-
ventricular physiology, and the impact of surgery on ventricular volume and pressure 
loading. Furthermore, these studies demonstrate that the potential clinical utility for BNP 
determinations as a part of management after cardiac surgery may depend upon analyzing 
patterns of change, as opposed to single time points. Moreover, relevant patterns of change 
may differ between cardiac defects and age groups. 
In fact, Berry and colleagues studied 20 neonates, infants, and children undergoing various 
stages of palliation for cardiac defects with single ventricle physiology(Berry et al. 2007). They 
found that BNP levels were highest in neonates undergoing a Norwood procedure compared 
with patients undergoing bidirectional cavopulmonary anastomosis or a Fontan procedure. 
They also found that postoperative BNP levels were predictive of hospital length of stay and 
postoperative inotropic support.Likewise, Hsu and colleagues measured perioperative BNP 
levels in 36 infants and children undergoing bidirectional cavopulmonary anastomosis (n=25) 
or total cavopulmonary connection (n=11)(Hsu et al. 2008). Plasma BNP levels were measured 
before and at various time points after surgery. They found that BNP levels increased after 
surgery, peaking at 12 hours in most patients. In the bidirectional cavopulmonary anastomosis 
group, patients with a 12-hour BNP level of ≥500 pg/mL had a longer duration of mechanical 
ventilation, intensive care unit stay, and hospital stay. A 12-hour BNP level of ≥500 pg/mL 
had a sensitivity of 80% and a specificity of 80% for predicting an unplanned surgical or 
transcatheter cardiac intervention, including transplantation. In the total cavopulmonary 
connection group, preoperative BNP levels were highest in patients with total cavopulmonary 
connection failure compared with patients with a good outcome, whereas postoperative BNP 
levels were not predictive of outcome.Importantly, preoperative cardiac catheterization data 
did not correlate with these outcomes in either group.  
5.2 BNP in patients requiring mechanical support after cardiac surgery 
Chikovani and colleagues studied the potential utility of BNP levels in the assessment of 
native myocardial performance in ten neonates and infants being supported with 
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extracorporeal life support (ECLS) after cardiac surgery(Chikovani et al. 2007). In particular, 
alterations in BNP during weaning trials off of ECLS were determined and compared to 
other biochemical markers, including lactate and the AVDO2.This study did not find 
associations between long-term outcome and alterations in lactate and the AVDO2 during 
trials off ECLS. However, an increase in BNP during the final trial off ECLS had a sensitivity 
of 80% and a specificity of 100% for predicting the need for an unplanned operation or death 
within 3 months.  A notable finding of this study was that BNP levels decreased during 
trials off of ECLS support (which were accomplished through the use of a bridge placed in 
the ECLS circuit, allowing mechanical support to be diverted away from the patient before 
the ECLS cannulae were removed) in patients who were successfully separated from ECLS 
after a trial. Since trials off ECLS were associated with increased cardiac filling (increased 
central venous pressures) in all patients, this study suggests that BNP levels may be 
regulated by additional mechanisms (other than just myocyte stretch). Furthermore, during 
trials off of ECLS, inotropic support, lactate levels and the AVDO2 increased in all patients 
(both those who successfully separated from ECLS and those who did not), suggesting that 
BNP levels may capture myocardial performance in a unique manner.  
In a similar earlier study, Huang and colleagues studied fifteen pediatric patients requiring 
ECLS for cardiogenic shock(Huang et al. 2006). Eleven of the fifteen patients developed 
shock after cardiac surgery. These investigators did not find an association between BNP 
levels during the course of ECLS and survival after ECLS. However, they did find that BNP 
levels on the first and fourth day following separation from ECLS were significantly higher 
in nonsurvivors than survivors(Huang et al. 2006). 
5.3 Long-term outcomes 
Koch and colleagues measured BNP levels in 130 children and adolescents (mean age of 16.1 
years) with a history of surgically repaired tetralogy of Fallot, at a mean time of 13±6.5 years 
after repair. They also performed exercise testing and echocardiograms. BNP levels were 
increased above normal gender and age specific values in 60% of the patients, but were less 
than 200 pg/ml in all patients(Koch et al. 2010). BNP levels were higher in patients awaiting 
pulmonary valve replacement, and in those in NYHA class II compared to class I. 
Furthermore, BNP levels correlated with right ventricular dilatation and the severity of 
tricuspid and pulmonary valve regurgitation, and were inversely correlated with exercise 
time. In addition, BNP levels increased over time in patients awaiting pulmonary valve 
replacement and decreased after surgery. The authors suggested that BNP levels might aid 
in the long-term management of these patients, particularly in the timing of pulmonary 
valve replacement.  
Pietrzak and Werner conducted a similar study, in which they measured NT-proBNP levels 
in 20 adolescents (10 to 17 years of age) during a follow-up period of 7 to 16 years after 
repair of tetralogy of Fallot(Pietrzak and Werner 2009). They found that NT-proBNP levels 
were higher in those patients than in age matched healthy controls. NT-proBNP levels were 
higher in patients who had undergone repair with a transannular patch compared to those 
who underwent repair without a transannular patch. Furthermore, NT-proBNP levels were 
increased in patients with: QRS prolongation during exercise testing, severe pulmonary 
regurgitation, and severe triscuspid regurgitation. Likewise, Dodge-Khatami and colleagues 
measured plasma NT-proBNP levels and obtained cardiac magnetic resonance imaging in 
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23 patients with repaired tetralogy of Fallot, severe pulmonary insufficiency, and increased 
right ventricular end-diastolic volume that were undergoing pulmonary valve 
replacement(Dodge-Khatami et al. 2006). Log-NT-proBNP levels were inversely correlated 
with right ventricular ejection fraction before and 6 months after surgery. NT-proBNP 
levels, right ventricular end-diastolic volume, and pulmonary insufficiency all decreased by 
6 months after surgery.  
These three studies differed from a study by Apitz and colleagues. These investigators 
measured BNP levels and recorded pressure-volume loops using conductance catheters in 
16 adolescents (median age of 14.2 years) with a known history of right ventricular dilation 
(NYHA class I, and Ross class 0) secondary to pulmonary regurgitation after repair of 
tetralogy of Fallot(Apitz et al. 2009). Latent right ventricular dysfunction was defined as 
impaired contractility (calculated by the slope of the end-systolic pressure-volume relation) 
in response to a dobutamine infusion. Latent right ventricular dysfunction was identified in 
5 patients, but no clear relationship with BNP levels could be observed. The difference 
between this study and those of Koch, Pietrzak, and Dodge-Khatami may relate to the 
severity of disease, suggesting that BNP may not be useful in detecting subclinical 
deterioration in this patient population. 
In a small pilot study, Paul and colleagues measured BNP levels before and after surgical 
repair of ventricular septal defects in 14 patients who were less than 2 years of age(Paul et 
al. 2009). Mean BNP levels decreased by 94 pg/ml after repair. Longitudinal analysis found 
that there was a weak inverse correlation between the postoperative change in BNP and 
postoperative weight gain (weight z-score change per month). 
Recently, Atz and colleagues described their findings in a study of 510 children (6-18 years 
of age), who were enrolled in the Pediatric Heart Network Fontan cross-sectional study(Atz 
et al. 2011). The patients had all undergone 3rd stage palliation of single ventricle cardiac 
defects with a Fontan procedure (median time from Fontan of 8.2 years). The distribution of 
BNP levels in these patients were highly skewed, but were generally within the normal 
range (median 13 pg/ml). However, logBNP levels were independently associated with a 
history of pre-Fontan systolic dysfunction, and post-Fontan complications, including 
thrombosis. LogBNP levels were higher in patients with atrial-to-pulmonary connections 
compared to extracardiac conduits. Furthermore, increased logBNP levels were associated 
with a lower level of physical functioning, chronotropic index during exercise, diastolic 
dysfunction, and greater ventricular mass measured by cardiac magnetic resonance 
imaging.  
In a similar study, Koch and colleagues measured plasma BNP levels in 67 patients after a 
modified Fontan procedure(Koch et al. 2008). Although there was a wide range, BNP levels 
were normal in 81% of the patients, with a median value of 13 pg/ml. Levels were not 
different between patients with right or left ventricular morphology. BNP levels were higher 
in patients in NYHA class II compared to those in class I, and were positively correlated 
with the severity of AV valve regurgitation. Likewise, Man and colleagues measured plasma 
BNP levels and assessed ventricular function (by tissue Doppler assessments, acoustic 
quantification, and myocardial performance index) in 35 asymptomatic patients who had 
previously undergone a Fontan procedure(Man and Cheung 2007). Comparisons were made 
to 34 healthy controls. Although BNP levels were low in the Fontan group (median 21 
pg/ml), they were higher than the control group. Moreover, BNP levels were inversely 
correlated with ventricular function, particularly diastolic function.  
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6. Conclusion 
The essential relationship between BNP production by the cardiac ventricle and increased 
myocyte stretch is the foundation for the potential use of BNP as a biomarker in any 
condition in which abnormal ventricular loading conditions are primarily involved in the 
pathophysiology. To date, plasma BNP determinations have not attained the same clinical 
prominence in pediatric patients as in adults. The growing utilization of BNP 
determinations in the care of adult patients likely stems from the ability to make clinical 
decisions, indeed to titrate therapy, in response to BNP levels(Troughton et al. 2000). Thus, a 
widespread use of BNP in pediatric patients is restrained by the scarcity of data that 
supports BNP guided therapies. It is likely that this discrepancy between the adult and 
pediatric experience relates, in part, to the number of investigations. However, compared to 
adult CHF, pediatric cardiac diseases resulting in ventricular dysfunction and CHF are far 
more heterogeneous. In fact, coronary artery disease is the leading cause of CHF in adults, 
whereas pediatric CHF may result from a wide spectrum of congenital cardiac defects and 
various cardiomyopathies. Moreover, clinically relevant cutoff values for plasma BNP levels 
within these various disease processes are not well established or are completely unknown. 
Nonetheless, the ability to readily quantify plasma BNP levels is attractive as few markers 
are so directly related to the pathobiology of the cardiac ventricle. This is particularly true in 
the management of critically ill pediatric patients, where we often employ surrogate 
markers of disease severity, such as serum lactate levels, that reflect global processes as 
opposed to organ specific functioning. 
Based on the studies outlined above, it is clear that BNP determinations can offer valuable 
clinical information to aid in the management of neonates, infants, and children undergoing 
surgical repair of cardiac defects. It is also clear, however, that the information is unlikely to 
come from single cut-off values that can be generalized across populations. Rather, a clinical 
utility for BNP determinations will likely come from an advanced understanding of 
expected perioperative patterns of change in BNP levels – patterns that will differ between 
age groups and specific cardiac defects. Furthermore, future studies must begin to evaluate 
the utility of guiding therapy in response to plasma BNP values. Fortunately, the ease of 
measuring BNP levels should facilitate these studies. For now the available data 
demonstrate that BNP has emerged as a novel biomarker with great potential.  
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